Safety, pharmacokinetics and pharmacodynamics of NXC736, a novel sphingosine‐1‐phosphate receptor modulator

Documenti analoghi

• Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG‐750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG‐745)
  di: Byungwook Kim, et al.
  Pubblicazione: (2024)
• Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure
  di: Juliane Rascher, et al.
  Pubblicazione: (2024)
• Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
  di: Kexu Yang, et al.
  Pubblicazione: (2026)
• Clinical study of the pharmacokinetics and pharmacodynamics of Xininurad tablets in patients with renal impairment
  di: Xiaoni Wang, et al.
  Pubblicazione: (2025)
• Personalized parathyroid hormone therapy for hypoparathyroidism: Insights from pharmacokinetic‐pharmacodynamic modelling
  di: Maira Visscher, et al.
  Pubblicazione: (2024)